{
    "clinical_study": {
        "@rank": "56",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 06, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04320615"
        },
        "id_info": {
            "org_study_id": "WA42380",
            "secondary_id": "2020-001154-22",
            "nct_id": "NCT04320615"
        },
        "brief_title": "A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia",
        "acronym": "COVACTA",
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia",
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche",
                "agency_class": "Industry"
            }
        },
        "source": "Hoffmann-La Roche",
        "oversight_info": {
            "is_fda_regulated_drug": "Yes",
            "is_fda_regulated_device": "No"
        },
        "brief_summary": {
            "textblock": "This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of\n      tocilizumab (TCZ) compared with a matching placebo in combination with standard of care (SOC)\n      in hospitalized patients with severe COVID-19 pneumonia."
        },
        "overall_status": "Not yet recruiting",
        "start_date": {
            "@type": "Anticipated",
            "#text": "April 3, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "September 30, 2021"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "August 31, 2021"
        },
        "phase": "Phase 3",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "allocation": "Randomized",
            "intervention_model": "Parallel Assignment",
            "primary_purpose": "Treatment",
            "masking": "Double (Participant, Investigator)"
        },
        "primary_outcome": {
            "measure": "Clinical Status Assessed Using a 7-Category Ordinal Scale",
            "time_frame": "Day 28"
        },
        "secondary_outcome": [
            {
                "measure": "Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours",
                "time_frame": "Up to 60 days"
            },
            {
                "measure": "Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status",
                "time_frame": "Up to 60 days"
            },
            {
                "measure": "Incidence of Mechanical Ventilation",
                "time_frame": "Up to 60 days"
            },
            {
                "measure": "Ventilator-Free Days to Day 28",
                "time_frame": "Up to Day 28"
            },
            {
                "measure": "Organ Failure-Free Days to Day 28",
                "time_frame": "Up to Day 28"
            },
            {
                "measure": "Incidence of Intensive Care Unit (ICU) Stay",
                "time_frame": "Up to 60 days"
            },
            {
                "measure": "Duration of ICU Stay",
                "time_frame": "Up to 60 days"
            },
            {
                "measure": "Time to Clinical Failure",
                "time_frame": "From first dose to time of death, mechanical ventilation, ICU admission, or study withdrawal (whichever occurs first, for up to 60 days)"
            },
            {
                "measure": "Mortality Rate",
                "time_frame": "Days 7, 14, 21, 28, and 60"
            },
            {
                "measure": "Time to Hospital Discharge",
                "time_frame": "Up to 60 days"
            },
            {
                "measure": "Duration of Time on Supplemental Oxygen",
                "time_frame": "Up to 60 days"
            },
            {
                "measure": "Percentage of Participants with Adverse Events",
                "time_frame": "Up to 60 days"
            },
            {
                "measure": "COVID-19 (SARS-CoV-2) Viral Load Over Time",
                "time_frame": "Up to 60 days"
            },
            {
                "measure": "Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity",
                "time_frame": "Up to 60 days"
            },
            {
                "measure": "Proportion of Participants with Post-Treatment Infection",
                "time_frame": "Up to 60 days"
            },
            {
                "measure": "Serum Concentration of IL-6",
                "time_frame": "Up to 60 days"
            },
            {
                "measure": "Serum Concentration of sIL-6R",
                "time_frame": "Up to 60 days"
            },
            {
                "measure": "Serum Concentration of Ferritin",
                "time_frame": "Up to 60 days"
            },
            {
                "measure": "Serum Concentration of C-Reactive Protein (CRP)",
                "time_frame": "Up to 60 days"
            },
            {
                "measure": "Serum Concentration of TCZ",
                "time_frame": "Up to 60 days"
            }
        ],
        "number_of_arms": "2",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "330"
        },
        "condition": "COVID-19 Pneumonia",
        "arm_group": [
            {
                "arm_group_label": "Tocilizumab (TCZ) Arm",
                "arm_group_type": "Experimental",
                "description": "Participants will receive 1 intravenous (IV) infusion of TCZ, dosed at 8 mg/kg, up to a maximum dose 800 mg. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement."
            },
            {
                "arm_group_label": "Placebo Arm",
                "arm_group_type": "Placebo Comparator",
                "description": "Participants will receive 1 IV infusion of placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement."
            }
        ],
        "intervention": [
            {
                "intervention_type": "Drug",
                "intervention_name": "Tocilizumab (TCZ)",
                "description": "Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen or show no improvement.",
                "arm_group_label": "Tocilizumab (TCZ) Arm"
            },
            {
                "intervention_type": "Drug",
                "intervention_name": "Placebo",
                "description": "Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.",
                "arm_group_label": "Placebo Arm"
            }
        ],
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Hospitalized with COVID-19 pneumonia confirmed per WHO criteria (including a positive\n             PCR of any specimen; e.g., respiratory, blood, urine, stool, other bodily fluid) and\n             evidenced by chest X-ray or CT scan\n\n          -  SPO2 </=93% or PaO2/FiO2 <300 mmHg\n\n        Exclusion Criteria:\n\n          -  Known severe allergic reactions to TCZ or other monoclonal antibodies\n\n          -  Active tuberculosis (TB) infection\n\n          -  Suspected active bacterial, fungal, viral, or other infection (besides COVID-19)\n\n          -  In the opinion of the investigator, progression to death is imminent and inevitable\n             within the next 24 hours, irrespective of the provision of treatments\n\n          -  Have received oral anti-rejection or immunomodulatory drugs (including TCZ) with the\n             past 6 months\n\n          -  Participating in other drug clinical trials (participation in COVID-19 anti-viral\n             trials may be permitted if approved by Medical Monitor)\n\n          -  Pregnant or breastfeeding, or positive pregnancy test in a pre-dose examination\n\n          -  Treatment with an investigational drug within 5 half-lives or 30 days (whichever is\n             longer) of randomization (investigational COVID-19 antivirals may be permitted if\n             approved by Medial Monitor)\n\n          -  Any serious medical condition or abnormality of clinical laboratory tests that, in the\n             investigator's judgment, precludes the patient's safe participation in and completion\n             of the study\n\n          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 10 x upper limit\n             of normal (ULN) detected within 24 hours at screening or at baseline (per local lab)\n\n          -  Absolute neutrophil count (ANC) < 1000/mL at screening and baseline (per local lab)\n\n          -  Platelet count < 50,000/mL at screening and baseline (per local lab)"
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "N/A",
            "healthy_volunteers": "No"
        },
        "overall_official": {
            "last_name": "Clinical Trials",
            "role": "Study Director",
            "affiliation": "Hoffmann-La Roche"
        },
        "overall_contact": {
            "last_name": "Reference Study ID Number: WA42380 www.roche.com/about_roche/roche_worldwide.htm",
            "phone": "888-662-6728",
            "email": "global-roche-genentech-trials@gene.com"
        },
        "verification_date": "March 2020",
        "study_first_submitted": "March 23, 2020",
        "study_first_submitted_qc": "March 23, 2020",
        "study_first_posted": {
            "@type": "Actual",
            "#text": "March 25, 2020"
        },
        "last_update_submitted": "March 26, 2020",
        "last_update_submitted_qc": "March 26, 2020",
        "last_update_posted": {
            "@type": "Actual",
            "#text": "March 30, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        },
        "condition_browse": {
            "mesh_term": "Pneumonia"
        },
        "patient_data": {
            "sharing_ipd": "Yes",
            "ipd_description": "Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com).\nFurther details on Roche's criteria for eligible studies are available here: https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm"
        }
    }
}